Increasing evidence indicates that DHHC cysteine-rich domain-containing proteins (DHHC proteins) are protein acyltransferases. Although multiple DHHC proteins are found in eukaryotes, characterization has been examined for only a few. Here, we have cloned all the yeast and human DHHC genes and investigated their intracellular localization and tissue-specific expression. Most DHHC proteins are localized in the ER and/or Golgi, with a few localized in the plasma membrane and one in the yeast vacuole.
Introduction
Many proteins, especially those involved in signaling events, are modified by palmitoylation on a cysteine residue. Palmitoylation has been shown to regulate protein stability, intracellular localization, and activities, as well as protein-protein and protein-lipid interactions [1, 2] . Palmitoylation occurs post-translation and is reversible, implying that the modified proteins are regulated through a palmitoylation-depalmitoylation cycle.
Although palmitoylation was first described over 30 years ago, the responsible genes have only recently been identified. In 2002, yeast genetic approaches identified two DHHC cysteine-rich domain-containing proteins (referred to here DHHC proteins), Akr1 and Erf2, as protein acyltransferases (PATs), with the Cys residue of the DHHC motif forming an acyl-intermediate [3, 4] . The DHHC cysteine-rich domain is a highly conserved region found in multiple eukarotic proteins (7 in yeast and 23 in mouse; Fig.   1 ) [5] . There is increasing evidence that DHHC proteins other than Akr1 and Erf2 also act as PATs [6] [7] [8] [9] [10] [11] [12] .
It is unclear why so many DHHC proteins exist in a single organism. One explanation is that each DHHC protein might act on specific substrate(s). Indeed, several yeast genetic studies have demonstrated that each substrate is palmitoylated mainly by a single responsible PAT [3, 4, 6, 7, 13] . It is also possible that DHHC proteins differ in their intracellular localization or tissue-specific expression patterns.
However, only limited information exists regarding these characteristics [3, 6, 7, 10, 12, [14] [15] [16] [17] [18] . Therefore, in the present study we cloned all yeast and human DHHC genes and 4 examined their intracellular localization and tissue-specific expression. These analyses revealed that each DHHC protein exhibits a distinguishing localization (ER, Golgi, vacuole, or plasma membrane) and tissue distribution.
Materials and methods

Yeast strain and media
The Saccharomyces cerevisiae strains used were SEY6210 [19] and KHY128 [20] .
Cells were grown either in YPD medium (1% yeast extract, 2% peptone, and 2% glucose) or in synthetic complete (SC) medium containing nutritional supplements.
Cell culture and transfection
Human embryonic kidney (HEK) 293T cells were grown in Dulbecco's modified Eagle's medium (D6429; Sigma) containing 10% FCS and supplemented with 100 units/ml penicillin and 100 µg/ml streptomycin, in 0.3% collagen-coated dishes.
Transfections were performed using Lipofectamine Plus TM Reagent (Invitrogen).
Plasmids
Yeast 2 µ-based high-copy-number plasmids encoding C-terminally triple HA (3xHA)-tagged DHHC proteins were used (specifically pAK826, SWF1-3xHA; pAK827, PFA3-3xHA; pAK828, PFA4-3xHA; pAK829, PFA5-3xHA; pAK830, ERF2-3xHA;
pAK245, AKR1-3xHA; and pAK247, AKR2-3xHA). The pAK290 plasmid, a derivative of pRS423 (HIS3 marker) [21] , was constructed to produce a 3xHA-tagged protein. The yeast DHHC genes were amplified from S288C genomic DNA (Invitrogen) using appropriate primers, as described in Tables 1 and 2 . The amplified fragments were cloned into the pAK290 plasmid.
The pUG23 plasmid, a yeast expression vector constructed to produce a fusion 6 protein with a C-terminal enhanced green fluorescent protein (EGFP) under the control of the MET25 promoter, was a gift from J. H. Hegemann. The pAK843 (SWF1-EGFP), pAK844 (PFA3-EGFP), pAK845 (PFA4-EGFP), and pAK846 (PFA5-EGFP) plasmids were constructed as follows. The SWF1, PFA3, PFA4, and PFA5 genes were amplified from pAK826, pAK827, pAK828, and pAK829 plasmids, respectively, using appropriate primers (SWF1, SWF1-F2 and SWF1-R1; PFA3, PFA3-F2 and PFA3-R1;
PFA4, PFA4-F2 and PFA4-R1; and PFA5, PFA5-F2 and PFA5-R1). The amplified fragments were cloned into the pUG23 plasmid.
Human DHHC genes were amplified using respective primers and templates as described in Tables 1 and 2 were also each cloned into pCE-puro 3xFLAG-1 vector, which had been designed to produce an N-terminal 3xFLAG-tagged protein, to create the respective pCE-puro 3xFLAG-DHHCx plasmid.
Reverse transcription (RT)-PCR
First-strand cDNAs from various human tissues (Human MTC TM panels I and II) were purchased from TAKARA Bio (Shiga, Japan). Each DHHC cDNA and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA were amplified by PCR using the tissue cDNAs and primers as described in Table 3 .
Immunoblotting
Immunoblotting was performed as described previously [20, 22] . Anti-HA Y-11 (0.2 µg/ml; Santa Cruz Biotechnology, Santa Cruz, CA), anti-FLAG M2 (1 µg/ml; Stratagene, La Jolla, CA), anti-Myc PL14 (1 µg/ml; Medical & Biological Laboratories, Nagoya, Japan), and actin (1/400 dilution; SIGMA) antibodies were used as primary antibodies. HRP-conjugated anti-mouse or anti-rabbit IgG F(ab') 2 fragment (both from Amersham Biosciences, Piscataway, NJ, and diluted 1:7500) were used as secondary antibodies. Labeling was detected using an ECL TM kit (Amersham Biosciences).
Fluorescence microscopy
Immunofluorescence microscopic analyses of cultured cells and yeast were done as 8 described previously [20, 23] . Anti-HA Y-11 (2 µg/ml), anti-Myc PL14 (2.5 µg/ml),
anti-Myc A-14 (1 µg/ml; Santa Cruz Biotechnology), anti-calreticulin (1/400 dilution;
Alexis Biochemicals, Lausen, Switzerland), anti-GM130 (1/100 dilution; BD Biosciences, San Jose, CA), and anti-FLAG M2 (0.5 µg/ml) antibodies were used as primary antibodies. Secondary antibodies included Alexa 488-conjugated anti-rabbit antibody, Alexa 488-conjugated anti-mouse antibody, Alexa 594-conjugated anti-rabbit antibody, and Alexa 594-conjugated anti-mouse antibody (each at 5 µg/ml; Invitrogen).
Vacuoles in yeast cells were imaged by treatment with 20 µM FM4-64, a vacuolar membrane-staining dye (Invitrogen), at 30˚C for 30min. Cells were washed with medium, mounted on slides, and analyzed by fluorescence microscopy using an AxioSkop 2 plus microscope (Carl Zeiss, Oberkochen, Germany).
Results
Intracellular localization of yeast DHHC proteins
To investigate the localization of yeast DHHC proteins, all yeast DHHC genes (SWF1, PFA3, PFA4, PFA5, ERF2, AKR1, and AKR2) were cloned and expressed as C-terminally 3xHA-tagged proteins under their own promoters. Pfa3-, Pfa5-, Akr1-, Akr2-, and Erf2-3xHA were readily detected by immunoblotting using anti-HA antibodies ( Fig. 2A) . However, the amounts of Swf1-3xHA and Pfa4-3xHA were very low. Because these proteins were visualized by the same detection system used for the other proteins, it is reasonable to consider that the detected amounts reflected the strength of their promoters.
Using the same constructs, we performed indirect immunofluorescent microscopic analyses ( Fig. 2B ). Staining patterns of both Akr1-3xHA and Akr2-3xHA were discontinuous, characteristic of proteins associated with the Golgi apparatus.
Erf2-3xHA staining appeared as two ring patterns corresponding to the endoplasmic reticulum (ER), a bright ring around the nucleus (nuclear ER) and a faint one near the cell surface (cortical ER). Pfa3-3xHA was detected in a ring pattern. The rings were determined to correspond to the vacuoles, since the fluorescence of the EGFP-tagged Pfa3 completely merged with the vacuolar membrane-staining dye, FM4-64 (Fig. 3 ).
The localizations of Akr1, Erf2, and Pfa3 were consistent with previous reports [3, 6, 14, 15 ].
We could not detect any fluorescence for Swf1-, Pfa4-, or Pfa5-3xHA using this staining method (data not shown). Therefore, we prepared EGFP fusion constructs under an inducible MET25 promoter. Yeast cells expressing EGFP, or Pfa3-, Pfa4-, Pfa5-, or Swf1-EGFP were treated with FM4-64 (Fig. 3) . EGFP itself was detected in the cytosol. In contrast, the fluorescence of Pfa3-EGFP merged completely with the FM4-64 staining of the vacuolar membrane, and that of Pfa4-EGFP appeared as two rings, indicative of placement at the ER. The Pfa5-EGFP signal was weak but detectable at the plasma membrane, and in some cells at vacuole-vacuole junctions. Although we still could not detect Swf1-EGFP, even as an EDFP-fusion protein, Swf1 has been reported to be localized in the ER [7] . Altogether, these results indicate that yeast DHHC proteins differ in their intracellular localization.
Intracellular localization of human DHHC proteins
We searched for DHHC genes in the human gene database. Although 23 mouse DHHC genes (DHHC-1 to -23) have been reported [8] , in humans the DHHC-23 gene is missing. Therefore, we cloned the other 22 DHHC genes (DHHC-1 to -22) and expressed them in HEK 293T cells as N-terminally His 6 -Myc-tagged proteins. Cell lysates were subjected to immunoblotting with an anti-Myc antibody (Fig. 4A ).
Although most of the DHHC proteins were substantially detectable, DHHC-1, -5, -16, -19, and -21 were not or only faintly detected. Therefore, constructs of these genes, and DHHC-2 for comparison, were prepared for expression in cells as N-terminally 3xFLAG-tagged proteins. In immunoblots using an anti-FLAG antibody, DHHC-1, -5, -19, and -21 were readily detectable, although DHHC-16 was still only faintly detected (Fig. 4B ).
We next investigated the intracellular localization of the His 6 -Myc-DHHC or 3xFLAG-DHHC proteins by indirect immunofluorescence microscopy ( Fig. 5) .
DHHC-1, -6, -10, -11, -13, -14, and -19 exhibited reticular staining patterns characteristic of ER proteins. We indeed confirmed such localization by overlapping the image with the staining pattern of calreticulin, an ER-resident protein ( Fig.6 and data not shown). Aberrant ER structures were observed in some DHHC-6, -10, or -11
-expressing cells, probably due to artificial effects of the overproduction of these proteins. A bright, round ER was detected in the DHHC-6 -expressing cells, whereas the ER was condensed in the DHHC-10 or DHHC-11 -expressing cells (data not shown).
DHHC-3, -4, -7, -8, -15, -17, and -18 exhibited perinuclear staining patterns, indicative of placement at the Golgi apparatus (Fig. 5) . We confirmed such co-localization by also staining the Golgi marker GM130 (Fig. 6 and data not shown).
DHHC-2, -9, -12, and -22 were detected both in the ER and the Golgi (Figs. 5 and 6 ).
Thus, most of the DHHC proteins were localized in the ER and/or Golgi, except DHHC-5, -20, and -21, which were localized in the plasma membrane (Fig. 5) mRNA was highly expressed in testis but weakly in thymus and small intestine.
DHHC-20 mRNA was observed in the placenta and testis, with weak expression detected in heart, lung, liver, and thymus. DHHC-2 and -15 mRNAs were almost absent in all tissues tested. Only faint expression was observed in kidney and testis for DHHC-2 mRNA and in heart, brain, lung, kidney, thymus, and small intestine for DHHC-15 mRNA. In conclusion, each DHHC mRNA exhibits a characteristic tissue-specific expression pattern.
Discussion
In the present study we investigated the intracellular localization of yeast and human DHHC proteins and found that each protein exhibits a characteristic localization ( Table   5 ). The most frequent organelles in which DHHC proteins were localized included the ER and the Golgi apparatus. In contrast, Pfa5 and DHHC-5, -20, and -21 were localized at the plasma membrane. Yeast Pfa3 alone was localized in the vacuole, and no human DHHC protein was found to be localized in the equivalent mammalian organelle, the lysosome. Since we were detecting overproduced but not endogenous proteins, the possibility cannot be excluded that overproduction caused spill over of some proteins into other organelles. Therefore, preparation of antibodies against each DHHC protein and their usage in localization studies will be required. However, our methods may have an advantage in elucidating specific functions for each DHHC protein.
Palmitoylation is a dynamic process, and several proteins, especially those involved in signal transduction, such as the heterotrimeric G protein G s α, the β 2 -adrenergic receptor, and endothelial nitric oxide synthase, undergo an acylated-deacylated cycle [26] [27] [28] . The plasma membrane-localized Pfa5 and DHHC-5, -20, and -21 proteins are candidates for PATs involved in this dynamic cycle. On the other hand, the ER-and/or Golgi-localized DHHC proteins may act on de novo synthesized proteins in stimulus-independent processes such as membrane localization and delivery to organelles.
Using their tissue-specific mRNA expression patterns (Fig. 7) (Fig. 7) . Substantial expression of DHHC-20 mRNA was observed in placenta and testis, although weak expression was also detected in other tissues. Only faint expression in some tissues was observed for DHHC-2 or -15 mRNA. It is possible that these genes are expressed in specific tissues that were not examined in this study.
Occasionally, two amplified bands were observed for a DHHC mRNA (Fig. 7) ; the most apparent example being DHHC-7 mRNA. We cloned the upper band and found that it represented an alternative splicing isoform that contains an additional 111 bp (data not shown). Since this isoform was expressed in specific tissues such as placenta, lung, liver, thymus, and small intestine, it is possible that it possesses tissue-specific functions.
Recent reports have indicated that some DHHC genes are related to certain pathologies: DHHC-2, to a colorectal cancer, a hepatocellular carcinoma, and a nonsmall cell lung cancer [24] ; DHHC-8, to schizophrenia [29] ; and DHHC-15, to X-linked mental retardation [30] . However, the substrates of these proteins are unclear at present. It has been suggested that DHHC proteins differ in substrate specificity with some overlap [8] . Therefore, future studies are required to elucidate the specific substrate(s) and physiological/pathological function(s) of each DHHC protein. Table 4 . The cells were then stained with anti-HA antibodies (left panels) and 4',6-diamidino-2-phenylindole (DAPI) (middle panels), and the staining patterns compared in merged images (right panels). Bar, 3 µm. Table 3 ) and PCR, mRNAs of DHHC-1 through -22 and GAPDH were amplified from human tissue cDNAs or from plasmids encoding each DHHC gene.
Figure legends
1 Table 1 . Primers used in this study
The restriction sites created are underlined.
1 Table 2 . Templates and primers used for amplifying DHHC genes 
DHHC-20
EST clone (BI464803) DHHC20-F1 and DHHC20-R1 DHHC20-Q1 and DHHC20-Q1c DHHC20-Q2 and DHHC20-Q2c
DHHC-21
Human liver cDNA DHHC21-F1 and DHHC21-R1
DHHC-22 EST clone (BU167563) DHHC22-F1 and DHHC22-R1 --------------------------------------------------------------------
1 Table 3 . 
Primers used in the RT-PCR ---------------------------------------------------------------
DHHC-18
DHHC18-F2 and DHHC18-R1
